1.99
+6.42%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Voyager Therapeutics
From its filings with the US Securities and Exchange Commission
Voyager Therapeutics is based in Lexington, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker VYGR. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $40.4m and a net loss of $119.7m. At that date it held total assets of $252.3m and shareholders' equity of $196.1m.
We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Our pipeline includes programs for Alzheimer’s disease, or AD; Friedreich’s ataxia, or FA; Parkinson’s disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of our programs are derived from our TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which we have used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Some of our programs are wholly-owned, and some are advancing with licensees and collaborators, including Alexion, AstraZeneca Rare Disease, or Alexion; Novartis Pharma AG, or Novartis; Neurocrine Biosciences, Inc., or Neurocrine; and Transition Bio, Inc., or Transition Bio.
We are advancing our own proprietary pipeline of drug candidates for neurological diseases, with a focus on AD. Our wholly-owned prioritized pipeline includes two tau targeting programs: VY1706, a tau silencing gene therapy for AD, and VY7523, an anti-tau antibody for AD. VY1706 is a gene therapy that leverages an intravenously delivered TRACER Capsid containing a vectorized small interfering RNA specifically targeting tau mRNA.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Nov 2015
- Employees
- 141
- Website
- voyagertherapeutics.com ↗
- Head office
- 75 HAYDEN AVENUE, LEXINGTON, MA, 02421
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Michael HigginsIndependent Chairman of the Board, since 2015$227,500
- Dr. Alfred SandrockPresident, Chief Executive Officer, Director, since 2022$3.4m
- Dr. Nathan JorgensenChief Financial Officer, Principal Financial Officer, Principal Accounting Officer$1.9m
- Ms. Robin SwartzChief Operating Officer, Chief Business Officer$1.4m
- Dr. Todd CarterChief Scientific Officer
- Ms. Jacquelyn Fahey SandellChief Legal Officer$1.7m
- Dr. Toby FergusonChief Medical Officer$3.0m
- Dr. Jude OnyiaDirector$189,000
- Dr. Grace ColonIndependent Director$192,435
- Mr. James GeraghtyIndependent Director$210,000
- Dr. Steven HymanIndependent Director$202,000
- Dr. Catherine MackeyIndependent Director$197,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 51
- Environment
- 53
- Social
- 62
- Governance
- 36
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Voyager Therapeutics Inc has a strong research and development pipeline, allowing them to develop innovative therapies for neurological diseases.
- The company has experienced and talented scientists and researchers who possess specialized knowledge in gene therapy, enabling them to stay at the forefront of the industry.
- Voyager Therapeutics Inc has established strategic partnerships and collaborations with reputable organizations, which provides access to additional resources, expertise, and funding.
Weaknesses
- The company is heavily reliant on the success of its research and development efforts, and any setbacks or delays in clinical trials could negatively impact its financial position and investor confidence.
- Voyager Therapeutics Inc has limited marketing and commercialization experience, which may pose challenges when it comes to effectively promoting and selling their therapies once approved.
- The company's dependency on external funding sources, such as grants and partnerships, makes it vulnerable to changes in the availability and terms of such funding.
Opportunities
- The increasing prevalence of neurological disorders presents a significant market opportunity for Voyager Therapeutics Inc to develop and market their therapies.
- Continuous advancements in gene therapy and the exploration of new technologies provide the company with a chance to further enhance and expand their treatment options.
- Expansion into international markets can grant Voyager Therapeutics Inc access to a broader patient population and potentially increase their revenue streams.
Threats
- Regulatory challenges and stringent approval processes pose a threat to Voyager Therapeutics Inc's ability to bring their therapies to market in a timely manner.
- Competition from larger pharmaceutical companies with more financial resources and established market presence may limit Voyager Therapeutics Inc's market share and ability to gain traction.
- Changes in healthcare policies and reimbursement models could impact the affordability and accessibility of Voyager Therapeutics Inc's therapies, making it difficult to generate revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.